COC Guidance Statements 2021

3.25    The Committee continued to develop the guidance statement series during 2021. This included finalising revisions to the cancer risk characterisation methods (G06) statement. 

3.26    Updates to the guidance on hazard identification and characterisation (G03), the use of biomarkers in carcinogenic risk assessment (G04) and alternatives to the two-year bioassay (G07) are ongoing and these are expected to be finalised in 2022.